BRIEF published on 06/20/2024 at 13:05, 5 months 1 day ago Theralase Successfully Repurposes Non-Cancer Drugs for Cancer Therapy Cancer Therapy Theralase Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/20/2024 at 13:05, 5 months 1 day ago Theralase réutilise avec succès des médicaments non anticancéreux pour le traitement du cancer Recherche Préclinique Thérapie Contre Le Cancer Theralase Rutherrin Réutilisation De Médicaments
PRESS RELEASE published on 06/20/2024 at 13:00, 5 months 1 day ago Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy Theralase® Technologies Inc. announces successful preclinical research in drug repurposing for cancer therapy using Rutherrin®, demonstrating increased efficacy in destroying cancer cells Theralase Technologies Inc. Cancer Therapy Rutherrin Drug Repurposing Preclinical Research
BRIEF published on 06/19/2024 at 13:05, 5 months 2 days ago Rutherrin® démontre une réponse complète dans le cancer du poumon au niveau préclinique Theralase Cancer Du Poumon Étude Préclinique Rutherrin Régression Tumorale
BRIEF published on 06/19/2024 at 13:05, 5 months 2 days ago Rutherrin® Demonstrates Complete Response in Lung Cancer Preclinically Preclinical Study Theralase Lung Cancer Rutherrin Tumor Regression
PRESS RELEASE published on 06/19/2024 at 13:00, 5 months 2 days ago Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically Theralase® Technologies Inc. announces promising results of Rutherrin® in treating Non-Small Cell Lung Cancer animal model with x-ray activation. Research shows tumor regression & improved survival rates Theralase® Technologies Inc. Rutherrin® Tumor Regression Non-Small Cell Lung Cancer X-ray Activation
BRIEF published on 06/18/2024 at 13:05, 5 months 3 days ago Rutherrin® Enhances Immunotherapy Efficacy in Preclinical Studies Cancer Treatment Theralase® Immunotherapy Rutherrin® Checkpoint Inhibitors
BRIEF published on 06/18/2024 at 13:05, 5 months 3 days ago Rutherrin® améliore l'efficacité de l'immunothérapie dans les études précliniques Theralase® Immunothérapie Traitement Du Cancer Rutherrin® Inhibiteurs De Points De Contrôle
PRESS RELEASE published on 06/18/2024 at 13:00, 5 months 3 days ago Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically Theralase Technologies Inc. announces preclinical research results showing Rutherrin® enhances immunotherapy efficacy by reducing PD-L1 proteins in cancer cells. The advancement aims to improve cancer treatment outcomes Theralase Technologies Inc. Cancer Treatment Immunotherapy Rutherrin PD-L1 Proteins
BRIEF published on 06/14/2024 at 22:50, 5 months 6 days ago Avis de rappel d'assemblée générale annuelle et extraordinaire des actionnaires de Theralase® Actionnaires Theralase® Réunion Virtuelle AGSM Présentation Zoom
Published on 11/21/2024 at 22:05, 28 minutes ago Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Published on 11/21/2024 at 21:50, 43 minutes ago Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Published on 11/21/2024 at 20:15, 2 hours 18 minutes ago Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Published on 11/21/2024 at 20:10, 2 hours 23 minutes ago For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform
Published on 11/21/2024 at 20:00, 2 hours 33 minutes ago Victory for New York Homeowners: Petroff Amshen LLP Blocks Lender’s Repeated Foreclosure Attempt
Published on 11/21/2024 at 19:01, 3 hours 32 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/21/2024 at 18:36, 3 hours 57 minutes ago Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Published on 11/21/2024 at 17:58, 4 hours 35 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/21/2024 at 17:51, 4 hours 41 minutes ago LIGHTON announces highly successful IPO on Euronext Growth Paris.
Published on 11/21/2024 at 17:51, 4 hours 41 minutes ago LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.
Published on 11/21/2024 at 06:58, 15 hours 35 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 15 hours 35 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 15 hours 35 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 1 day 2 hours ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 1 day 3 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
